Prof Nicolas Girard speaks to ecancer at the ESMO 2018 congress in Munich, he discusses his research on EGFR mutations in adenocarcinoma of the lung.

He highlights some particularly rare EGFR mutations and the significance of these in terms of treatment and outcomes.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.